Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Deborah T. Blumenthal*, Thierry Gorlia, Mark R. Gilbert, Michelle M. Kim, L. Burt Nabors, Warren P. Mason, Monika E. Hegi, Peixin Zhang, Vassilis Golfinopoulos, James R. Perry, Do Hyun Nam, Sara C. Erridge, Benjamin W. Corn, Rene O. Mirimanoff, Paul D. Brown, Brigitta G. Baumert, Minesh P. Mehta, Martin J. van den Bent, David A. Reardon, Michael WellerRoger Stupp*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

INIS

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science